DGIdb - HERCEPTIN Drug Record

HERCEPTIN wikidata:Q29005931

Alternate Names:

rxcui:101306

Drug Info:

(0 More Sources)

Publications:

Yakes et al., 2002, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action., Cancer Res.
Láng et al., 2006, [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer]., Magy Onkol
Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.
Zhang et al., 2005, Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer., Mol. Cell Proteomics

HERCEPTIN HSPB2

Interaction Score: 4.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16048908

Sources:
NCI
HERCEPTIN PIK3CG

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12124352

Sources:
NCI
HERCEPTIN ERBB2

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17216002 15581051

Sources:
NCI

NCI: HERCEPTIN

Version: 14-September-2017

Alternate Names:

C1647 NCI drug code

Drug Info:

Publications:

Yakes et al., 2002, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action., Cancer Res.

Láng et al., 2006, [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer]., Magy Onkol

Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.

Wikidata: wikidata:Q29005931
- Version: 12-August-2020
Alternate Names:

Drug Info:

Publications: